Some Hormonal And Hematological Changes Accompanied With Type 2 Diabetes Mellitus
Beberapa Perubahan Hormonal dan Hematologi yang Disertai dengan Diabetes Melitus Tipe 2
DOI:
https://doi.org/10.21070/ijhsm.v2i2.123Keywords:
T2DM, Hormones, Blood parametersAbstract
The goal of this research to examine the alterations in a few and hormonal and hematological markers that took place in persons with type 2 diabetes Mellitus T2DM. The current research is being conducted at the Al-Hussein Hospital's diabetes and endocrinology center in the province of Al-Muthanna. There were 200 participants in the study: 100 were T2DM patients and 100 were controls. Patients and controls ranged in age from 24 to 50. In this study, spectrophotometry was used to assess fasting blood sugar (FBS) at 546 nm, the Sysmax-Kx-21 was used to measure hematological parameters (RBC, Hb, RDW, WBC, PLT, and MPV), and the ELSA technique was used to detect hormones (TSH, T3, and T4).The FBS of T2DM patients is considerably upper than that of control patients (P<0.05), according to the results. However, the findings indicate that patients with T2MD had meaningfully lower ranks of TSH, T3, and T4 when paralleled to the control grouping. Hematological parameter data indicate that patients with T2DM had significantly lower RBC and Hb when paralleled to the control grouping, but considerably upper RDW, WBC, PLT, and MPV (P<0.05) when paralleled to the control grouping.
Highlights:
- Higher FBS in T2DM patients compared to healthy controls.
- Lower TSH, T3, T4 in T2DM group than controls.
- Altered blood markers: Low RBC, Hb; high RDW, WBC, PLT, MPV.
Keywords: T2DM , Hormones , Blood parameters
References
[1]. D. G. Gardner and D. Shoback, Greenspan’s Basic and Clinical Endocrinology, 9th ed. New York, NY, USA: McGraw-Hill Medical, 2011, ch. 17.
[2]. K. A. Gajewska, R. Biesma, S. Sreenan, and K. Bennett, "Prevalence and Incidence of Type 1 Diabetes in Ireland: A Retrospective Cross-Sectional Study Using National Pharmacy Claims Data from 2016," BMJ Open, vol. 10, no. 4, pp. e035535, Apr. 2020.
[3]. Y. Zheng, S. H. Ley, and F. B. Hu, "Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications," Nature Reviews Endocrinology, vol. 14, no. 2, pp. 88–98, Feb. 2018.
[4]. A. M. Duarte, M. P. Guarino, S. Barroso, and M. M. Gil, "Phytopharmacological Strategies in the Management of Type 2 Diabetes Mellitus," Foods, vol. 9, no. 3, pp. 271, Mar. 2020.
[5]. M. Amiri, "Diabetes Mellitus Type 2; An International Challenge," Annals of Research in Dialysis, vol. 1, no. 1, pp. 1–2, 2016.
[6]. S. M. Hoffner and H. Sex, "Obesity, Fat Distribution, Type 2 Diabetes and Insulin Resistance: Epidemiological and Clinical Correlation," International Journal of Obesity and Related Metabolic Disorders, vol. 24, pp. 556–558, 2005.
[7]. Y. S. Eom, J. R. Wilson, and V. J. Bernet, "Links Between Thyroid Disorders and Glucose Homeostasis," Diabetes & Metabolism Journal, vol. 46, no. 2, pp. 239–256, Apr. 2022.
[8]. C. Aguayo-Mazzucato et al., "Thyroid Hormone Promotes Postnatal Rat Pancreatic β-Cell Development and Glucose-Responsive Insulin Secretion Through MAFA," Diabetes, vol. 62, no. 5, pp. 1569–1580, May 2013.
[9]. C. Verga Falzacappa et al., "Thyroid Hormone T3 Counteracts STZ Induced Diabetes in Mouse," PLoS One, vol. 6, no. 5, pp. e19839, May 2011.
[10]. S. Antwi-Baffour, R. Kyeremeh, S. O. Boateng, L. Annison, and M. A. Seidu, "Haematological Parameters and Lipid Profile Abnormalities Among Patients with Type-2 Diabetes Mellitus in Ghana," Lipids in Health and Disease, vol. 17, no. 1, pp. 1–9, Dec. 2018.
[11]. G. Shin, K. Jang, M. Kim, J. H. Lee, and H. J. Yoo, "Inflammatory Markers and Plasma Fatty Acids in Predicting WBC Level Alterations in Association with Glucose-Related Markers: A Cross-Sectional Study," Frontiers in Immunology, vol. 11, pp. 629, Apr. 2020.
[12]. R. B. Passey, R. L. Gillum, J. B. Fuller, F. M. Urry, and M. L. Giles, "Evaluation and Comparison of 10 Glucose Methods and the Reference Method Recommended in the Proposed Product Class Standard (1974)," Clinical Chemistry, vol. 23, no. 1, pp. 131–139, Jan. 1977.
[13]. N. W. Tietz, Fundamentals of Clinical Chemistry, 3rd ed. Philadelphia, PA, USA: W.B. Saunders, 1995, pp. 469–478.
[14]. L. E. Braverman, "Evaluation of Thyroid Status in Patients with Thyrotoxicosis," Clinical Chemistry, vol. 42, no. 1, pp. 174–178, Jan. 1996.
[15]. E. L. Mazzaferri and H. Gharib, "Thyroxine Suppressive Therapy in Patients with Nodular Thyroid Disease," Annals of Internal Medicine, vol. 128, no. 5, pp. 386–394, Mar. 1998.
[16]. B. H. Estridge and A. P. Reynolds, Basic Clinical Laboratory Techniques, 5th ed. Clifton Park, NY, USA: Delmar Cengage Learning, 2008, pp. 302.
[17]. J. H. McDonald, Handbook of Biological Statistics, 3rd ed. Baltimore, MD, USA: Sparky House Publishing, 2014.
[18]. A. K. Jimoh et al., "Spectrum of Thyroid Function Test Among Type 2 Diabetic Patients Attending a Rural Health Facility, Southwest Nigeria: A Hospital-Based Study," SAGE Open Medicine, vol. 10, pp. 20503121221097625, Apr. 2022.
[19]. A. Berbudi, N. Rahmadika, A. I. Tjahjadi, and R. Ruslami, "Type 2 Diabetes and Its Impact on the Immune System," Current Diabetes Reviews, vol. 16, no. 5, pp. 442–449, 2020.
[20]. American Diabetes Association, "6. Glycemic Targets: Standards of Medical Care in Diabetes—2020," Diabetes Care, vol. 43, Suppl. 1, pp. S66–S76, Jan. 2020.
[21]. N. T. Gursoy and E. Tuncel, "The Relationship Between the Glycaemic Control and Hypothalamus-Pituitary-Thyroid Axis in Diabetic Patients," Turkish Journal of Endocrinology and Metabolism, vol. 12, pp. 163–168, 1999.
[22]. F. Goglia, M. Moreno, and A. Lanni, "Action of Thyroid Hormones at the Cellular Level: The Mitochondrial Target," FEBS Letters, vol. 452, no. 3, pp. 115–120, May 1999.
[23]. S. Stanická et al., "Insulin Sensitivity and Counter-Regulatory Hormones in Hypothyroidism and During Thyroid Hormone Replacement Therapy," Clinical Chemistry and Laboratory Medicine, vol. 43, no. 7, pp. 715–720, 2005.
[24]. M. T. Hays, "Thyroid Hormone and the Gut," Endocrine Research, vol. 14, no. 2–3, pp. 203–224, 1988.
[25]. G. Dimitriadis et al., "The Effects of Insulin on Transport and Metabolism of Glucose in Skeletal Muscle From Hyperthyroid and Hypothyroid Rats," European Journal of Clinical Investigation, vol. 27, no. 6, pp. 475–483, 1997.
[26]. P. Cettour-Rose et al., "Hypothyroidism in Rats Decreases Peripheral Glucose Utilisation, a Defect Partially Corrected by Central Leptin Infusion," Diabetologia, vol. 48, no. 4, pp. 624–633, 2005.
[27]. C. Ochon, I. Tauveron, and C. Dejax, "Response of Glucose Disposal to Hyperinsulinaemia in Human Hypothyroidism and Hyperthyroidism," Clinical Science, vol. 104, pp. 7–15, 2003.
[28]. F. Jabeen, H. A. Rizvi, F. Aziz, and A. Z. Wasti, "Hyperglycemic-Induced Variations in Hematological Indices in Type 2 Diabetics," International Journal of Advanced Research, vol. 1, no. 8, pp. 322–334, 2013.
[29]. B. Biadgo, M. Melku, S. M. Abebe, and M. Abebe, "Hematological Indices and Their Correlation With Fasting Blood Glucose Level and Anthropometric Measurements in Type 2 Diabetes Mellitus Patients in Gondar, Northwest Ethiopia," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 9, pp. 91–99, 2016.
[30]. R. H. Asmah et al., "Relationship Between Oxidative Stress and Hematological Indices in Patients With Diabetes in the Ghanaian Population," Clinical Diabetes and Endocrinology, vol. 1, no. 7, pp. 4–8, 2015.
[31]. Y. I. Cho, M. P. Mooney, and D. J. Cho, "Hemorheological Disorders in Diabetes Mellitus," Journal of Diabetes Science and Technology, vol. 2, no. 6, pp. 1130–1138, 2008.
[32]. N. Abdel and M. Hamed, "Alterations in Hematological Parameters: Could It Be a Marker in Diabetes Mellitus?" BAOJ Diabetes, vol. 2, no. 1, pp. 1–9, 2016.
[33]. M. Sahay et al., "Diabetes and Anemia: International Diabetes Federation (IDF)–Southeast Asian Region (SEAR) Position Statement," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 11, pp. 685–695, 2017.
[34]. Z. Saad and A. Shehri, "The Relationship Between Some Biochemical and Hematological Changes in Type 2 Diabetes Mellitus," Biomedical Research and Therapy, vol. 4, no. 11, pp. 1760–1774, 2017.
[35]. G. L. Salvagno, F. Sanchis-Gomar, A. Picanza, and G. Lippi, "Red Blood Cell Distribution Width: A Simple Parameter With Multiple Clinical Applications," Critical Reviews in Clinical Laboratory Sciences, vol. 52, no. 2, pp. 86–105, 2015.
[36]. H. Sherif, N. Ramadan, M. Radwan, E. Hamdy, and R. Rabab, "Red Cell Distribution Width as a Marker of Inflammation in Type 2 Diabetes Mellitus," Life Sciences Journal, vol. 10, no. 3, pp. 1501–1507, 2013.
[37]. G. Çakırca and M. M. Çelik, "Relationships Between Glycemic Control and Platelet Indices, Atherogenic Index of Plasma and Vitamin D in Patients With Type 2 Diabetes," E-Journal of Cardiovascular Medicine, vol. 7, no. 3, pp. 147–152, 2019.
[38]. M. Kizilgul et al., "Components of the Complete Blood Count in Type 2 Diabetes Mellitus With Inadequate Glycemic Control," Dicle Medical Journal, vol. 45, no. 2, pp. 113–120, 2018.
[39]. C. Olana, D. Seifu, M. K. C. Menon, and G. Natesan, "Abnormal Hematological Indices and Anthropometric Parameters Associated With Type 2 Diabetes," International Journal of Biomedical and Advance Research, vol. 10, no. 11, pp. 1–8, 2019.
[40]. R. H. Lee and W. Bergmeier, "Sugar Makes Neutrophils RAGE: Linking Diabetes-Associated Hyperglycemia to Thrombocytosis and Platelet Reactivity," The Journal of Clinical Investigation, vol. 127, no. 6, pp. 2040–2043, 2017.
[41]. M. Ravindra, D. Shilpa, and A. Shamim, "Platelet Indices in Type 2 Diabetes Mellitus and Their Association With Microvascular Complications," Panacea Journal of Medical Sciences, vol. 9, no. 1, pp. 23–28, 2019.
[42]. F. Jabeen, A. Fawwad, H. A. Rizvi, and F. Alvi, "Role of Platelet Indices, Glycemic Control and hs-CRP in Pathogenesis of Vascular Complications in Type-2 Diabetic Patients," Pakistan Journal of Medical Sciences, vol. 29, no. 1, pp. 152–156, 2013.
[43]. R. Kaur, M. Kaur, and J. Singh, "Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies," Cardiovascular Diabetology, vol. 17, no. 1, pp. 121, 2018.
[44]. N. Kakouros, J. J. Rade, A. Kourliouros, and J. R. Resar, "Platelet Function in Patients With Diabetes Mellitus: From a Theoretical to a Practical Perspective," International Journal of Endocrinology, vol. 2011, Art. no. 742719, 2011.
